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ABSTRACT
Introduction In addition to favoring renal disease 
progression, renal ‘hyperfiltration’ has been associated 
with an increased risk of death, though it is unclear 
whether and how excess mortality is related to 
increased renal function. We investigated whether renal 
hyperfiltration is an independent predictor of death in 
patients with type 2 diabetes from the Renal Insufficiency 
And Cardiovascular Events Italian multicenter study.
Research design and methods This observational, 
prospective cohort study enrolled 15 773 patients with 
type 2 diabetes consecutively attending 19 Italian diabetes 
clinics in 2006–2008. Serum creatinine, albuminuria, 
cardiovascular risk factors, and complications/
comorbidities were assessed at baseline. Vital status on 31 
October 2015 was retrieved for 15 656 patients (99.26%). 
Patients were stratified (A) by absolute estimated 
glomerular filtration rate (eGFR) values in eGFR deciles 
or Kidney Disease: Improving Global Outcomes (KDIGO) 
categories and (B) based on age- corrected thresholds 
or age and gender- specific 95th and 5th percentiles in 
hyperfiltration, hypofiltration, and normofiltration groups.
Results The highest eGFR decile/category and the 
hyperfiltration group included (partly) different individuals 
with similar clinical features. Age and gender- adjusted 
death rates were significantly higher in deciles 1, 9, and 
10 (≥103.9, 50.9–62.7, and <50.9 mL/min/1.73 m2, 
respectively) versus the reference decile 3 (92.9–97.5 
mL/min/1.73 m2). Mortality risk, adjusted for multiple 
confounders, was also increased in deciles 1 (HR 1.461 
(95% CI 1.175 to 1.818), p=0.001), 9 (1.312 (95% CI 
1.107 to 1.555), p=0.002), and 10 (1.976 (95% CI 1.673 
to 2.333), p<0.0001) versus decile 3. Similar results were 
obtained by stratifying patients by KDIGO categories. 
Death rates and adjusted mortality risks were significantly 
higher in hyperfiltering and particularly hypofiltering versus 
normofiltering individuals.
Conclusions In type 2 diabetes, both high- normal eGFR 
and hyperfiltration are associated with an increased risk 
of death from any cause, independent of confounders 
that may directly impact on mortality and/or affect GFR 
estimation. Further studies are required to clarify the 
nature of this relationship.
Trial registration number NCT00715481.
INTRODUCTION
Renal (ie, whole- kidney) hyperfiltration is 
commonly defined as a glomerular filtration 
Significance of this study
What is already known about this subject?
 ► Previous reports have shown that, in addition to fa-
voring renal disease progression, renal ‘hyperfiltra-
tion’ is associated with increased mortality.
 ► However, it is unclear whether (and how) the in-
creased risk of death is related to increased renal 
function or to confounders that may directly impact 
on mortality and/or affect assessment of estimated 
glomerular filtration rate (eGFR).
What are the new findings?
 ► This large, observational, prospective cohort study 
showed that the highest eGFR decile/category 
(above ~105 mL/min/1.73 m2) and the age (and 
gender-) corrected hyperfiltration groups included 
partly different individuals, though with similar clin-
ical features (ie, younger age, more frequently male 
and current smoker, more favorable cardiovascular 
risk profile, lower prevalence of comorbidities).
 ► In addition to low eGFR/hypofiltration, both high- 
normal eGFR and hyperfiltration were associated 
with an increased risk of death from any cause.
 ► Increased mortality risk was independent of con-
founders that may directly impact on mortality and/
or affect GFR estimation.
How might these results change the focus of 
research or clinical practice?
 ► In individuals with type 2 diabetes, not only reduced, 
elevated eGFR, either in the high- normal or in the 
hyperfiltration range, should be considered a risk 
factor for increased mortality.
 ► Further studies are required to establish whether 
the increased mortality risk is directly related to 
eGFR and to clarify the mechanisms underlying this 
relationship.
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rate (GFR) that exceeds 2 SD above mean GFR in healthy 
individuals,1 corresponding to values ranging from 130 
to 140 mL/min/1.73 m2.2 An elevated GFR has been 
reported in the early stage of both type 1 and type 
2 diabetes, with prevalence values of 10%–67% and 
6%–73%3 and average increases of approximately 27%4 
and 16%,5 respectively. Hyperfiltration has been reported 
also in non- diabetic obese individuals, though in most, 
but not all studies it was no longer observed when GFR 
was adjusted for body size.3 However, this definition of 
renal hyperfiltration does not consider a number of 
factors that impact on GFR variability, such as nephron 
endowment at birth, ethnicity, gender, and especially 
age.3 Indeed, after the age of 40 years, the threshold for 
hyperfiltration should be corrected for the annual GFR 
decline of 1 mL/min/1.73 m2.6 Moreover, identifica-
tion of hyperfiltration is complicated by the inaccuracy 
of serum creatinine- based GFR- estimating equations,3 
which systematically underestimate GFR, especially in 
the normal or increased range, in individuals with type 
2 diabetes.7
Renal hyperfiltration occurring in early diabetes and 
obesity is the result of an increased single- nephron GFR 
(SNGFR), the so- called glomerular hyperfiltration, which 
is caused by multiple mechanisms affecting the determi-
nants of glomerular ultrafiltration.8 Increased SNGFR 
may also occur despite normal or reduced whole- kidney 
GFR, as it represents an adaptive response for main-
taining renal function in several renal disorders. A supra-
physiological GFR elevation is considered a risk factor for 
adverse renal outcomes in diabetic individuals.3 Though 
not consistently, epidemiological surveys have in fact 
reported an association with subsequent GFR loss and 
development of microalbuminuria or macroalbuminuria 
in patients with type 1 and 2 diabetes.3 Likewise, under 
conditions of reduced renal mass, hyperfiltration in the 
residual nephrons is considered the main mechanism 
leading to further nephron loss and progression toward 
end- stage renal disease.9
In addition to favoring renal disease progression, 
renal hyperfiltration has been associated with increased 
mortality. A meta- analysis of general population and high- 
risk cohorts has shown an increased risk of death from 
any cause, but not from cardiovascular disease (CVD), 
in individuals with an estimated GFR (eGFR) ≥105 mL/
min/1.73 m2 and normoalbuminuria,10 a finding subse-
quently confirmed in people with and without diabetes or 
hypertension.11 12 However, this increased mortality risk 
has been interpreted as an effect of conditions such older 
age and severe comorbidities, which are characterized by 
low creatinine values due to reduced muscle mass rather 
than to increased renal function.10 12 A recent systematic 
review has suggested that renal hyperfiltration is indeed 
associated with a higher risk of death and CVD.13 Unfor-
tunately, the studies considered in this review were mostly 
retrospective and included individuals from either the 
general population or selected disease groups of various 
size and different risk, and only some of them reported 
measurements of albuminuria/proteinuria or were 
specifically focused on hyperfiltration. More importantly, 
most of these studies did not evaluate ‘hyperfiltering’ 
individuals, but only those falling in the highest eGFR 
category, which included people with high- normal eGFR 
values below the hyperfiltration threshold, at variance 
with older patients falling in other categories, who may 
have exceeded the age- corrected threshold.
The present analysis aimed at assessing whether renal 
hyperfiltration at baseline, defined as either the highest 
eGFR decile/category or age (and gender-) corrected 
hyperfiltration, is an independent predictor of subse-
quent death from any cause in the large cohort of indi-
viduals with type 2 diabetes from the Renal Insufficiency 




The RIACE is an observational, prospective cohort study 
on the impact of eGFR on morbidity and mortality in 
individuals with type 2 diabetes.14
Patients
The study population included 15 773 Caucasian patients 
(after excluding 160 individuals with missing or implau-
sible values), consecutively attending 19 hospital- based, 
tertiary referral diabetes clinics of the National Health 
Service throughout Italy in 2006–2008. Exclusion criteria 
were dialysis or renal transplantation.
All-cause mortality
The vital status of study participants on 31 October 2015 
was verified by interrogating the Italian Health Card data-
base (http:// sistemats1. sanita. finanze. it/ wps/ portal/), 
which provides updated and reliable information on all 
current Italian residents.15
Baseline measurements
Baseline data were collected using a standardized 
protocol across participating centers.14
Participants underwent a structured interview in 
order to collect the following information: age, smoking 
status, known diabetes duration, comorbidities, and 
current glucose, lipid, and blood pressure (BP)- lowering 
treatments.
Body mass index (BMI) was calculated from weight and 
height, whereas waist circumference was estimated from 
log- transformed BMI values16; BP was measured with a 
sphygmomanometer with the patients seated with the 
arm at the heart level.
Hemoglobin A1c (HbA1c) was measured by high- 
performance liquid chromatography using Diabetes 
Control and Complications Trials- aligned methods; 
triglycerides and total and high- density lipoprotein 
(HDL) cholesterol were determined in fasting blood 
samples by colorimetric enzymatic methods; low- density 
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lipoprotein (LDL) cholesterol was calculated by the Frie-
dewald formula.
The presence of diabetic kidney disease (DKD) was 
assessed by measuring albuminuria and serum creat-
inine, as previously detailed.14 17 Albumin excretion 
rate was obtained from 24 hours of urine collections 
or calculated from albumin- to- creatinine ratio in early- 
morning, first- voided urine samples, using a conversion 
formula developed in patients with type 1 diabetes and 
preliminarily validated in a subgroup of RIACE partici-
pants. Albuminuria was measured in fresh urine samples 
by immunonephelometry or immunoturbidimetry, in 
the absence of interfering clinical conditions. One to 
three measurements for each patient were obtained; in 
cases of multiple measurements, the geometric mean 
of 2–3 values was used for analysis. In individuals with 
multiple measurements, the concordance rate between 
the first value and the geometric mean was >90% for all 
albuminuria categories.17 Serum (and urine) creatinine 
was measured by the modified Jaffe method, traceable 
to Isotope- Dilution Mass Spectrometry, and eGFR was 
calculated by the Chronic Kidney Disease Epidemiology 
Collaboration equation.15
In each center, the presence of diabetic retinopathy 
(DR) was assessed by an expert ophthalmologist by 
dilated funduscopy. Patients with mild or moderate non- 
proliferative DR were classified as having non- advanced 
DR, whereas those with severe non- proliferative DR, 
proliferative DR, or maculopathy were grouped into the 
advanced DR category. DR grade was assigned based on 
the worse eye.18
Previous major acute CVD events, including myocar-
dial infarction, stroke, foot ulcer/gangrene/amputation, 
and coronary, carotid, and lower limb revascularization, 
were adjudicated based on hospital discharge records by 
an ad hoc committee in each center.19
Categorization of patients
For the purpose of the current analysis, the RIACE partic-
ipants were either stratified by absolute eGFR levels or 
categorized based on age (and gender-) adjusted eGFR 
threshold for hyperfiltration (and hypofiltration), as 
shown in online supplementary table S1. First, the cohort 
was divided into deciles of baseline eGFR values, from the 
highest (>104 mL/min/1.73 m2) to the lowest (<51 mL/
min/1.73 m2). As the highest decile approximately corre-
sponds to the high- normal G1 subcategory, patients were 
also stratified according to the following Kidney Disease: 
Improving Global Outcomes (KDIGO) eGFR catego-
ries and subcategories (mL/min/1.73 m2): G1a (≥105), 
G1b (90–104), G2 (60–89), G3a (45–59), G3b (30–44), 
G4–5 (<30).20 Then, participants were classified as hyper-
filtering if their baseline eGFR value was above an age- 
adjusted hyperfiltration threshold calculated according 
to the formula 130 mL/min/1.73 m2–1.0 mL/min/1.73 
m2 per year after 40 years of age.21 The remaining indi-
viduals were classified as normofiltering or hypofiltering 
based on whether their baseline eGFR value was above 
or below 60 mL/min/1.73 m2. According to previous 
studies,22 23 hyperfiltering and hypofiltering patients were 
also defined as individuals with eGFR values above the 
95th and below the 5th age and gender- specific percen-
tiles, respectively, whereas normofiltering individuals 
were those falling in between. As shown in online supple-
mentary figure S1, both percentiles were virtually iden-
tical in men and women; in addition, while there was a 
high concordance between the two definitions for hyper-
filtration, the 5th percentile threshold for hypofiltration 
was well below 60 mL/min/1.73 m2 for patients aged ≥60 
years, consistent with the view that both the upper and the 
lower limits of the normal range decrease with ageing.24
Statistical analysis
Data are expressed as mean±SD or median (IQR) 
for continuous variables, and number of cases and 
percentage for categorical variables. Comparisons among 
groups were performed by one- way analysis of variance or 
Kruskal- Wallis test, according to the parametric or non- 
parametric distribution of continuous variables, and by 
Pearson’s χ2 test for categorical variables.
Crude mortality rates were described as events per 1000 
patient- years, with 95% exact Poisson CIs and adjusted for 
age and gender by a Poisson regression model. Kaplan- 
Meier survival probabilities for all- cause mortality were 
estimated according to the above categorizations and 
differences were analyzed using the log- rank statistic. The 
HRs and their 95% CIs were estimated by Cox proportional 
hazards regression, using the ‘normal eGFR’ group (ie, the 
third decile and the G1b category) or the normofiltering 
group as reference. These analyses were adjusted for age 
and gender (model 1), plus albuminuria (model 2), plus 
CVD risk factors, that is, smoking, diabetes duration, HbA1c, 
BMI, triglycerides, total and HDL cholesterol, systolic and 
diastolic BP, and antihyperglycemic, lipid- lowering, antihy-
pertensive, and renin- angiotensin system (RAS) blocker 
treatment (model 3), and plus other complications, that 
is, DR grade and any CVD, and presence of severe comor-
bidity(ies), that is, chronic obstructive pulmonary disease, 
chronic liver disease and/or cancer (model 4).
All p values were two sided, and p<0.05 was considered 
statistically significant. Statistical analyses were performed 
using SPSS V.13.0 (SPSS, Chicago, IL, USA).
RESULTS
Valid information on vital status was retrieved for 15 656 
participants (99.3% of the cohort). At the time of the 
census, 3602 (23.0%) individuals had died; death rate 
was 31.0 per 1000 person- years (95% CI 30.0 to 32.0) over 
a mean follow- up of 7.4±2.1 years.25 26
Clinical features of participants by eGFR deciles/KDIGO 
categories
The clinical features of the RIACE participants strati-
fied by eGFR deciles are shown in table 1. From the first 
(highest) to the 10th (lowest) eGFR decile, the propor-
tion of male patients and current smokers and the levels 
4 BMJ Open Diab Res Care 2020;8:e001481. doi:10.1136/bmjdrc-2020-001481
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of LDL cholesterol and diastolic BP decreased, whereas 
age, age at diabetes diagnosis, diabetes duration, total 
cholesterol, systolic BP, pulse pressure, albuminuria, 
and prevalence of hypertension, dyslipidemia, DR, CVD, 
comorbidities, and insulin, lipid- lowering, antihyperten-
sive, and RAS blocker treatment increased from the first 
to the tenth decile. Similar differences were observed 
among the KDIGO eGFR categories (online supplemen-
tary table S2).
Association between eGFR deciles/KDIGO categories and 
mortality
Crude mortality rates increased from the first to the tenth 
decile, with lower values in decile 1 and higher values 
in deciles 4–10, as compared with decile 3. However, 
when adjusted for age and gender, mortality rates were 
significantly higher in deciles 1, 9, and 10 compared with 
decile 3 (table 2). Kaplan- Meier estimates (online supple-
mentary figure S2A) and unadjusted HRs (not shown) 
also increased from the first to the tenth decile. Again, 
when sequentially adjusting for confounders, mortality 
risk became significantly higher for decile 1 (HR 1.461 
(95% CI 1.175 to 1.818), p=0.001) and remained signifi-
cantly higher for deciles 9 (1.312 (95% CI 1.107 to 
1.555), p=0.002) and 10 (1.976 (95% CI 1.673 to 2.333), 
p<0.0001), compared with decile 3 (figure 1). Results 
were similar when patients were stratified by KDIGO eGFR 
categories. In particular, when sequentially adjusting for 
confounders, mortality risk increased approximately to 
the same extent for G1a (1.426 (1.169–1.740), p<0.0001) 
and G3a (1.332 (1.175–1.510), p<0.0001) and much 
more for G3b (1.963 (1.706–2.259), p<0.0001) and 
G4–5 (2.400 (2.001–2.878), p<0.0001) eGFR categories, 
compared with reference G1b category (online supple-
mentary figure S3).
Clinical features of participants by age (and gender-) 
corrected filtration status
While individuals with an eGFR >130 mL/min/1.73 m2 
were only 44 (0.3%), the number of hyperfiltering indi-
viduals rose to 644 (4.1%) and 774 (4.9%) using age- 
adjusted eGFR thresholds and age and gender- specific 
95th and 5th percentiles, respectively, for defining 
hyperfiltration. Though the majority of these individ-
uals (57.9% and 66.9%, respectively) fell in the first 
decile, there were also hyperfiltering patients falling in 
other deciles; conversely, the majority of individuals in 
the first decile were normofiltering (76.2% and 66.9%, 
respectively). Yet, the clinical features of hyperfiltering 
patients were similar to those of patients in the highest 
eGFR decile/category (table 3 and online supplementary 
table S3).
Association between age (and gender-) corrected filtration 
status and mortality
In hyperfiltering patients, unadjusted and age and gender- 
adjusted mortality rates (table 2), Kaplan- Meier estimates 
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(not shown) and adjusted HRs (figure 2) were all higher 
than in normofiltering and lower than in hypofiltering 
individuals. In model 4, mortality risk was increased in 
hyperfiltering (1.231 (1.049–1.444), p=0.011) and much 
more in hypofiltering (1.499 (1.387–1.620), p<0.0001) 
patients versus the normofiltering group. When using 
the age and gender- specific 95th and 5th percentiles, the 
extent of increase in mortality risk was similar for hyper-
filtering individuals (1.192 (1.021–1.391), p=0.026) and 
even more pronounced for hypofiltering patients (2.125 
Table 2 Mortality rates in the RIACE participants with valid information on vital status on 31 October 2015, stratified by eGFR 




Events per 1000 patient- 
years (95% CI), 
unadjusted P value
Events per 1000 patient- 
years (95% CI), age and 
gender adjusted P value
eGFR deciles
  1 1565 148 9.5 11.84 (10.08 to 13.92) 0.007 14.23 (11.68 to 17.33) <0.0001
  2 1566 170 10.9 13.65 (11.74 to 15.86) 0.149 11.07 (9.18 to 13.35) 0.119
  3 1566 196 12.5 15.87 (13.80 to 18.26) Ref 9.38 (7.85 to 11.21) Ref
  4 1565 261 16.7 21.74 (19.25 to 24.54) 0.001 9.93 (8.41 to 11.73) 0.544
  5 1566 330 21.1 28.17 (25.29 to 31.38) <0.0001 10.47 (8.93 to 12.27) 0.224
  6 1565 347 22.2 29.71 (26.74 to 33.00) <0.0001 10.66 (9.08 to 12.51) 0.154
  7 1566 333 21.3 28.35 (25.46 to 31.56) <0.0001 10.24 (8.70 to 12.04) 0.336
  8 1566 408 26.1 35.53 (32.25 to 39.15) <0.0001 11.57 (9.92 to 13.49) 0.016
  9 1566 545 34.8 50.32 (46.26 to 54.72) <0.0001 14.30 (12.35 to 16.55) <0.0001
  10 1565 864 55.2 92.51 (86.54 to 98.89) <0.0001 23.66 (20.60 to 27.17) <0.0001
Filtration status
  Hyper 644 169 26.2 36.32 (31.24 to 42.23) <0.0001 13.66 (11.30 to 16.51) 0.009
  Normo 12 306 2160 17.6 22.93 (21.98 to 23.92) Ref 10.81 (9.57 to 12.21) Ref
  Hypo 2706 1273 47.0 73.86 (69.91 to 78.03) <0.0001 19.84 (17.42 to 22.59) <0.0001
eGFR, estimated glomerular filtration rate; RIACE, Renal Insufficiency And Cardiovascular Events.
Figure 1 Cox proportional hazards regression adjusted for age and gender (A), plus albuminuria (B), plus CVD risk factors 
(C), plus complications/comorbidities (D), according to eGFR deciles. HRs (95% CI) for mortality are shown for each group; the 
green arrow indicates the first decile. CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate.
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Table 3 Baseline clinical features in the RIACE participants with valid information on vital status on 31 October 2015, 
stratified by age- adjusted filtration status
Variable Normofiltering Hyperfiltering Hypofiltering P value
n (%) 12 306 (78.6) 644 (4.1) 2706 (17.3)
eGFR (mL/min/1.73 m2) 86.3±13.6 108.0±14.0 46.0±11.2
(60.0–129.2) (74.5–176.0) (4.1–59.9)
Deaths, n (%) 2160 (17.6) 169 (26.2) 1273 (47.0) <0.0001
Age (years) 64.9±9.9 67.5±11.4 73.8±8.6 <0.0001
Gender, n (%)       <0.0001
  Females 5107 (41.5) 294 (45.7) 1353 (50.0)
  Males 7199 (58.5) 350 (54.3) 1353 (50.0)
Smoking status, n (%)       <0.0001
  Never 6891 (56.0) 368 (57.1) 1590 (58.8)
  Former 3413 (27.7) 157 (24.4) 837 (30.9)
  Current 2002 (16.3) 119 (18.5) 279 (10.3)
Diabetes duration (years) 12.4±9.7 11.9±9.8 17.2±11.1 <0.0001
Age at diagnosis (years) 52.6±11.0 55.6±12.2 56.6±12.0 <0.0001
HbA1c (mmol/mol) 58.6±16.2 59.6±18.8 60.7±16.9 <0.0001
Antihyperglycemic Tx, n (%)       <0.0001
  Lifestyle 1767 (14.4) 93 (14.4) 253 (9.3)
  Non- insulin 7791 (63.3) 405 (62.9) 1423 (52.6)
  Insulin 2748 (22.3) 146 (22.7) 1030 (38.1)
BMI (kg/m2) 29.0±5.1 28.5±5.7 29.1±5.1 0.021
Waist circumference (cm) 102.5±10.4 101.4±11.6 102.6±10.2 0.029
Triglycerides (mmol/L) 1.53±0.95 1.51±1.41 1.77±1.05 <0.0001
Total cholesterol (mmol/L) 4.78±0.97 4.77±1.05 4.79±1.05 0.957
HDL cholesterol (mmol/L) 1.30±0.35 1.36±0.37 1.24±0.36 <0.0001
Non- HDL cholesterol (mmol/L) 3.49±0.94 3.41±1.02 3.55±0.99 0.001
LDL cholesterol (mmol/L) 2.80±0.84 2.74±0.84 2.75±0.87 0.012
Dyslipidemia, n (%) 10 120 (82.2) 476 (73.9) 2260 (83.5) <0.0001
Lipid- lowering Tx, n (%) 5524 (44.9) 237 (36.8) 1477 (54.6) <0.0001
Systolic BP (mm Hg) 137.8±17.8 136.6±16.8 139.7±19.2 <0.0001
Diastolic BP (mm Hg) 79.1±9.3 77.9±9.2 77.5±9.9 <0.0001
Pulse pressure (mm Hg) 58.7±15.4 58.7±14.4 62.2±17.1 <0.0001
Hypertension, n (%) 10 378 (84.3) 521 (80.9) 2551 (94.3) <0.0001
Antihypertensive Tx, n (%) 8265 (67.2) 421 (65.4) 2386 (88.2) <0.0001
RAS blocker Tx, n (%) 6968 (56.6) 341 (53.0) 2031 (75.1) <0.0001
Antiplatelet Tx, n (%) 4507 (36.6) 260 (40.4) 1481 (54.7) <0.0001
Anticoagulant Tx, n (%) 409 (3.3) 16 (2.5) 244 (9.0) <0.0001
Albuminuria (mg/24 hours) 47.3±210.9 77.0±678.7 185.0±504.1 <0.0001
Albuminuria categories, n (%)       <0.0001
  Normoalbuminuria 9532 (77.5) 452 (70.2) 1476 (54.5)
  Microalbuminuria 2425 (19.7) 174 (27.0) 866 (32.0)
  Macroalbuminuria 349 (2.8) 18 (2.8) 364 (13.5)
Serum creatinine (μmol/L) 73.0±14.9 43.5±8.8 127.0±55.6 <0.0001
DR, n (%)       <0.0001
  No 9827 (79.9) 518 (80.4) 1844 (68.1)
Continued
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Variable Normofiltering Hyperfiltering Hypofiltering P value
  Non- advanced 1440 (11.7) 72 (11.7) 435 (16.1)
  Advanced 1039 (8.4) 54 (8.4) 427 (15.8)
CVD, n (%)       
  Any 2453 (19.9) 110 (17.1) 1057 (39.1) <0.0001
  Myocardial infarction 1173 (9.5) 51 (7.9) 518 (19.1) <0.0001
  Coronary revascularization 1090 (8.9) 39 (6.1) 450 (16.6) <0.0001
  Any coronary event 1628 (13.2) 68 (10.6) 700 (25.9) <0.0001
  Stroke 336 (2.7) 18 (2.8) 159 (5.9) <0.0001
  Carotid revascularization 548 (4.5) 13 (2.0) 295 (10.9) <0.0001
  Any cerebrovascular event 841 (6.8) 28 (4.3) 423 (15.6) <0.0001
  Ulcer/gangrene/amputation 341 (2.8) 20 (3.1) 195 (7.2) <0.0001
  Lower limb revascularization 273 (2.2) 7 (1.1) 170 (6.3) <0.0001
  Any peripheral event 548 (4.5) 24 (3.7) 311 (11.5) <0.0001
Comorbidities, n (%)       
  Any 2053 (16.7) 130 (20.2) 604 (22.3) <0.0001
  COPD 435 (3.5) 40 (6.2) 199 (7.4) <0.0001
  Chronic liver disease 1045 (8.5) 55 (8.5) 261 (9.6) 0.154
  Cancer 757 (6.2) 53 (8.2) 221 (8.2) <0.0001
Values are mean±SD or median (IQR) for continuous variables, and number of cases (percentage) for categorical variables.
BMI, body mass index; BP, blood pressure; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; DR, diabetic 
retinopathy; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; HDL, high- density lipoprotein; LDL, low- density lipoprotein; 
RAS, renin- angiotensin system; RIACE, Renal Insufficiency And Cardiovascular Events; Tx, treatment.
Table 3 Continued
Figure 2 Cox proportional hazards regression adjusted for age and gender (A), plus albuminuria (B), plus CVD risk factors (C), 
plus complications/comorbidities (D), according to age- adjusted filtration status. HRs (95% CI) for mortality are shown for each 
group. CVD, cardiovascular disease; Hyper, hyperfiltering; Hypo, hypofiltering; Normo, normofiltering.
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(1.899–2.379), p<0.0001), consistent with the lower 
threshold for reduced eGFR levels (online supplemen-
tary figure S4).
Association between other covariates and mortality
All the other covariates included in the regression models 
were significantly associated with mortality, especially age 
(HR ~1.09 per year), male gender (HR ~1.33), current 
smoking (HR ~1.25), insulin treatment (HR ~1.84), 
history of major acute CVD events (HR ~1.51), and 
severe comorbidity(ies) (HR ~1.65). Diabetes duration, 
BMI, systolic BP and, in some cases, triglycerides and RAS 
blocker treatment were excluded from the models.
DISCUSSION
This analysis of patients with type 2 diabetes from the 
RIACE cohort shows that ‘renal hyperfiltration’, regard-
less of how it is defined, is an independent predictor of 
subsequent death from any cause, thus suggesting that 
not only reduced, but also elevated eGFR may be associ-
ated with increased mortality in these individuals.
Previously, only two retrospective surveys focused 
exclusively on patients with type 2 diabetes and reported 
an increase in all- cause mortality among those in the 
highest eGFR category.27 28 In particular, Luo et al28 exam-
ined 4836 patients who had an acute stroke and found 
an increased risk of adverse stroke outcomes, including 
death, in those with an eGFR ≥120 and <45 mL/
min/1.73 m2, as compared with individuals with an eGFR 
of 90–119 mL/min/1.73 m2.28 While these data refer to 
a specific subset of patients with type 2 diabetes (and 
were not adjusted for albuminuria), Davis et al studied 
1296 individuals from the population- based Fremantle 
Diabetes Study and confirmed the J- shaped association 
between eGFR and mortality, with an increased risk for 
an eGFR ≥90 and particularly ≥120 mL/min/1.73 m2, 
though the lowest risk was surprisingly observed among 
individuals with an eGFR of 45–59 mL/min/1.73 m2.28 
In the prospective, much larger RIACE study, risk of 
death was significantly increased for an eGFR below ~60 
mL/min/1.73 m2 (deciles 9 and 10 or KDIGO catego-
ries G3–5) and above ~105 mL/min/1.73 m2 (decile 1 
or KDIGO category G1a), that is, starting from eGFR 
values in the high- normal range. Similar findings have 
been reported among 4201 adults with type 1 diabetes 
from the Finnish Diabetic Nephropathy Study.29 These 
data are consistent with previous large meta- analyses 
showing a J- shaped relationship between eGFR and all- 
cause mortality in both non- diabetic and diabetic indi-
viduals.10 11
However, the unique observation of our study is that 
an increased mortality risk was observed both in patients 
in the highest eGFR decile/category and in those above 
the age (and gender-) adjusted hyperfiltration thresh-
olds, despite the fact that these two groups included 
different individuals, at least partly, thus raising the ques-
tion whether the mechanisms involved are also different. 
In fact, the detrimental effects of hyperfiltration on the 
kidney have been related to the increase in glomerular 
capillary hydraulic pressure that ensues when the incre-
ment in effective renal blood flow is lower than the 
increment in GFR, as indicated by an increased filtra-
tion fraction.1 Unfortunately, as no filtration fraction 
data were available, the role of glomerular hypertension 
could not be evaluated in the RIACE cohort. Indeed, it is 
possible either that patients with reduced renal mass had 
glomerular hypertension despite eGFR values in the high- 
normal range but below the hyperfiltration threshold or 
that hyperfiltering individuals had no increase in glomer-
ular pressure, as occurs in living kidney donors, unless 
other factors superimpose,30 and in normal pregnancy, in 
which both efferent and afferent arterioles dilate and the 
increase in renal blood flow is greater than the increase 
in GFR.31 However, despite including different individ-
uals, the groups of participants with high- normal eGFR 
and hyperfiltration had quite similar clinical features, as 
in both cases patients were younger and more frequently 
male and current smoker and had a shorter diabetes 
duration and a lower prevalence of dyslipidemia, hyper-
tension, complications and severe comorbidities, as 
compared with patients with low eGFR/hypofiltration 
(and even those with normal eGFR/normofiltration). 
Based on these features, individuals with high- normal 
eGFR/hyperfiltration were apparently not at higher risk 
of death compared with those falling in other eGFR cate-
gories or filtration groups, a finding that has important 
implications for interpreting the increased mortality risk 
associated with increasing eGFR values.
Another important finding of our study is that the 
increased risk of death associated with high- normal 
eGFR or hyperfiltration (ie, ~1.5× and ~1.2×, respec-
tively) remained virtually unchanged after adjustment 
for a wide range of confounders that may affect mortality 
and/or GFR estimation and was of approximately the 
same order of magnitude of the increase in mortality risk 
associated with some of these covariates, including prev-
alent CVD and comorbidities. Conversely, the increased 
mortality risk associated with low eGFR or hypofiltration 
was attenuated by sequential adjustment for confounders, 
because of the worse risk profile of these individuals, but 
remained higher than with high- normal eGFR (except for 
the ninth decile or the G3a category) or hyperfiltration, 
respectively. The unchanged and residual mortality risk 
associated with high- normal eGFR/hyperfiltration and 
low eGFR/hypofiltration, respectively, may be explained 
by unmeasured confounders or by the inability of ‘statis-
tical’ adjustment to fully account for the impact of 
measured confounders. In addition, these findings raise 
a number of issues regarding the mechanisms underlying 
the relationship between high eGFR/hyperfiltration and 
mortality.
First, rather than the effect of supranormal renal 
function, with or without glomerular hypertension, this 
relationship may reflect the presence of confounders, 
which decrease serum creatinine levels, thus spuriously 
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increasing eGFR. Low muscle mass is usually associ-
ated with conditions such as older age, malnourishing, 
cancer and other severe comorbidities, which confer 
an increased risk of death, and sarcopenia is in fact 
associated with increased mortality.32 The interpreta-
tion that the increased mortality associated with high 
eGFR is due to GFR overestimation because of muscle 
wasting in high- risk individuals is supported by the find-
ings that the J- shaped association between creatinine- 
based eGFR and death was observed only for all- cause 
mortality,10–12 33 which includes death because of malig-
nancies and other chronic conditions associated with 
cachexia, and disappeared in younger individuals.34 This 
view is further strengthened by the observation that the 
relationship between renal function and mortality was 
linear when using cystatin C,33 35 36 which is not affected 
by muscle mass.37 However, the findings that high levels 
of measured GFR (by iohexol clearance) were also asso-
ciated with subclinical CVD38 and that hyperfiltration was 
related to increased mortality independent of lean body 
(muscle) mass39 argue against this interpretation. In our 
study, the increased risk of death associated with high- 
normal eGFR/hyperfiltration remained after adjustment 
for age, gender, BMI, and severe comorbidities.
Second, the association between high eGFR/hyper-
filtration and mortality may reflect early pathological 
changes occurring both in the kidney and in other 
vascular beds, possibly mediated by common mecha-
nisms including RAS and sympathetic nervous system 
activation, which may be responsible for both hyperfil-
tration and premature death, with the former that may 
act either as a marker or a mediator of the increased 
mortality risk.13 This concept is supported by the asso-
ciation of high eGFR/hyperfiltration with CVD risk 
factors,38 40 subclinical CVD,22 38 41 and CVD events.22 27 42 43 
However, high eGFR/hyperfiltration was not found to be 
associated with CVD mortality in most studies10–12 33 44 
and also the association with CVD events was not always 
observed.44 45 Indeed, in the RIACE cohort, individuals 
with high eGFR/hyperfiltration had a lower, not a higher 
prevalence of CVD and overall CVD (and non- CVD) risk 
at baseline, as compared with patients in the other eGFR 
deciles/categories or filtration groups. Moreover, though 
they were more often current smokers, a condition asso-
ciated with both high eGFR and mortality, the increased 
risk of death in individuals with high- normal eGFR/
hyperfiltration remained after adjustment for smoking 
status, consistent with a previous report.39
Third, the relationship between high eGFR/hyper-
filtration and death may be mediated through the 
promotion of DKD, a powerful risk factor for CVD and 
all- cause mortality.46 This interpretation is consistent 
with the concurrent renal and CVD protection with RAS 
blockers and particularly with sodium- glucose cotrans-
porter (SGLT2) inhibitors or glucagon- like peptide-1 
(GLP-1) receptor agonists.47 In fact, hyperfiltration in 
diabetes has been related to increased sodium reab-
sorption due to the upregulation of SGLTs and sodium 
hydrogen exchanger-3, the latter modulated by GLP-1.3 
The resulting decreased sodium delivery to the macula 
densa, which in obese individuals may derive also from 
compression of the thin loops of Henle,3 inhibits tubu-
loglomerular feedback, thereby reducing afferent arte-
riole resistance and increasing glomerular plasma flow 
and capillary hydraulic pressure.3 Moreover, imbalances 
in metabolic and neurohormonal factors, including RAS 
activation, act directly at the vascular level by reducing 
afferent more than efferent (or by increasing efferent) 
arteriole resistance.3
The observed association between increased risk of 
death and high- normal eGFR/hyperfiltration, indepen-
dent of confounders potentially affecting mortality and/
or GFR estimation, supports the concept that absolute 
or relative increases in eGFR might be considered a risk 
factor for all- cause mortality. However, further studies are 
needed for clarifying whether and how excess mortality 
is directly related to increased renal function. Further-
more, since our study was based on eGFR rather than 
on SNGFR, as all previous reports on the association 
between hyperfiltration and mortality, it was not possible 
to assess the role of glomerular hyperfiltration that, in 
individuals with reduced nephron endowment at birth 
or nephron loss after birth, may be associated also with 
normal or even reduced whole- kidney GFR.
A major strength of this study is that it analyzed exclu-
sively patients with type 2 diabetes comparing different 
criteria for defining ‘hyperfiltration’. Other strengths 
include the large sample size, the assessment of a wide 
range of clinical parameters, and the completeness of 
baseline and follow- up data. However, this study has 
several limitations. First, GFR estimation and lack of 
filtration fraction data and causes of death did not allow 
identifying individuals with renal hyperfiltration and 
those with glomerular hypertension and also evaluating 
the association of high eGFR/hyperfiltration with CVD 
mortality. However, measuring GFR (and renal plasma 
flow to calculate filtration fraction) is not feasible with 
such a large number of patients and, to date, only one 
study involving 1521 participants has used GFR measure-
ments to evaluate the association of elevated GFR with 
CVD events.38 Furthermore, though CVD is responsible 
for most of the excess mortality associated with diabetes, 
also cancer and non- CVD/non- cancer deaths are more 
frequent in diabetic versus non- diabetic individuals48 
and, as discussed above, all- cause, not CVD mortality 
has been consistently associated with ‘hyperfiltration’. 
Second, lack of data on SNGFR (and birth weight, which 
may be associated with reduced nephron endowment and 
increased SNGFR49) did not allow to establish the role 
of glomerular hyperfiltration in the increased mortality 
risk. However, SNGFR measurements require invasive 
procedures that are not applicable to large observational 
studies. Third, in patients with diabetes with normal or 
elevated GFR, serum creatinine reflects renal function 
less accurately than cystatin C,50 which, however, is not 
routinely measured in these individuals. Fourth, lack of 
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measurements of renal function over time did not allow 
assessing whether individuals with high eGFR/hyperfil-
tration developed more frequently renal disease during 
the follow- up. Fifth, lack of measurements of body compo-
sition did not allow to completely rule out the possibility 
of lower muscle mass in individuals with high- normal 
eGFR/hyperfiltration, though it was unlikely based on 
BMI and on the younger age and lower prevalence of 
severe comorbidities. Sixth, the study findings may not 
be applicable to the general ambulatory population, as 
only part of the individuals with type 2 diabetes attend 
diabetes clinics in Italy. Finally, the observational design 
makes causal interpretation impossible.
In conclusion, in individuals with type 2 diabetes, both 
high- normal eGFR and hyperfiltration are associated with 
an increased risk of death from any cause, independent 
of confounders that may directly impact on mortality 
and/or affect GFR estimation by reducing muscle mass. 
Further studies are required to establish whether the 
increased mortality risk is directly related to eGFR, either 
in the high- normal or the hyperfiltration range, and to 
clarify the mechanisms underlying this relationship.
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